Navigation Links
Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
Date:1/15/2012

NEW BRUNSWICK, N.J. Rutgers University and Massachusetts General Hospital (MGH) investigators have developed a novel strategy to protect the liver from drug-induced injury and improve associated drug safety.

In a report receiving advance online publication in the journal Nature Biotechnology, the team reports that inhibiting a type of cell-to-cell communication can protect against damage caused by liver-toxic drugs such as acetaminophen.

"Our findings suggest that this therapy could be a clinically viable strategy for treating patients with drug-induced liver injury," said Suraj Patel a postdoctoral researcher in the Center for Engineering in Medicine at MGH and the paper's lead author. "This work also has the potential to change the way drugs are developed and formulated, which could improve drug safety by providing medications with reduced risk of liver toxicity."

Drug-induced liver injury is the most common cause of acute liver failure in the U.S. and is also the most frequent reason for abandoning drugs early in development or withdrawing them from the market. Liver toxicity limits the development of many therapeutic compounds and presents major challenges to both clinical medicine and to the pharmaceutical industry.

Since no pharmaceutical strategies currently exist for preventing drug-induced liver injury, treatment options are limited to discontinuing the offending drug, supportive care and transplantation for end-stage liver failure.

The researchers investigated an approach that targets a liver's gap junctions hollow multimolecular channels that connect neighboring cells and allow direct communication between coupled cells. In the heart, gap junctions propagate the electrical activity required for synchronized contraction, but their role in the liver has not been well understood

Recent work has shown that gap junctions spread immune signals from injured liver cells to surrounding undamaged cells, amplifying inflammation and injury. The current study examined inhibiting the action of liver-specific gap junctions to limit drug-induced liver injury.

The researchers first used a strain of genetically mutated mice that lack a particular liver-specific gap junction. The mice were administered various liver-toxic drugs such as acetaminophen, a commonly used medication best known under the Tylenol brand name. Acetaminophen overdoses are the most frequent cause of drug-induced liver injury.

Compared to normal mice, those lacking liver gap junctions were fully protected against liver damage, inflammation and death caused by administration of liver-toxic drugs. The team then identified a small-molecule inhibitor of liver gap junctions that, when given with or even after the toxic drugs, protected the livers of normal mice against injury and prevented their death.

"This finding is very exciting and potentially very powerful from a number of basic science and clinical application standpoints, which we are continuing to explore," said Martin Yarmush, senior author of the report and the Paul and Mary Monroe Professor of Biomedical Engineering at Rutgers. "However, before we can think about applying this approach to patients, we need to know more about any off-target effects of gap junction inhibitors and better understand the long-term ramifications of temporarily blocking liver-specific gap junction channels."

Additionally, cell culture experiments indicated that blocking gap junctions limited the spread through liver cells of damaging free radicals and oxidative stress, suggesting a possible mechanism for the observed protection.


'/>"/>
Contact: Carl Blesch
cblesch@ur.rutgers.edu
732-932-7084 x616
Rutgers University
Source:Eurekalert  

Related medicine news :

1. Even privately insured have hard time getting psychiatric care in Massachusetts: Harvard study
2. Massachusetts health-care reform increased access to care, particularly among disadvantaged
3. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
4. Study examines impact of Massachusetts health law on emergency department visits
5. Support for Massachusetts landmark health reform law rises in 2011
6. Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses
7. Season of birth and celiac disease in Massachusetts children
8. Massachusetts reform hasnt stopped medical bankruptcies: Harvard study
9. Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
10. Massachusetts physician groups improving patient experience, study finds
11. Massachusetts Institute of Technology IDs new cancer drug target
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of ... Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities ... before the big event. The invitation-only gifting suite, held this year at the W ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to bring patients ... office. Beginning in January, Miami Dental Specialists will offer the non-metal implants as a ... office to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
(Date:2/11/2016)... INC. (NasdaqCM: PDEX) today announced financial results for its fiscal ... filed its Quarterly Report on Form 10-Q for the second ... Commission today. --> --> ... --> Net sales for the three months ended ... million from $2.8 million for the three months ended December ...
Breaking Medicine Technology: